India-developed meningococcal meningitis vaccine bags WHO prequalification

13 July 2023

The World Health Organization (WHO) has prequalified the meningococcal meningitis vaccine developed by the Serum Institute of India (SII) and PATH, a global non-profit.

The first conjugate vaccine against meningococcal meningitis named MenFive, the vaccine is a result of a 13-year collaboration between the SII and PATH, and is designed to protect against five primary causes of meningococcal meningitis in Africa. Funding for its development came from the UK government’s Foreign, Commonwealth and Development Office.

Prequalification by the WHO implies that the vaccine complies with high standards of quality, safety, and efficacy and allows MenFive to be procured by United Nations agencies as well as Gavi, The Vaccine Alliance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK